Real-time monitoring of oxygen uptake in hepatic bioreactor shows CYP450-independent mitochondrial toxicity of acetaminophen and amiodarone
- 1.3k Downloads
Prediction of drug-induced toxicity is complicated by the failure of animal models to extrapolate human response, especially during assessment of repeated dose toxicity for cosmetic or chronic drug treatments. In this work, we present a 3D microreactor capable of maintaining metabolically active HepG2/C3A spheroids for over 28 days in vitro under stable oxygen gradients mimicking the in vivo microenvironment. Mitochondrial respiration was monitored using two-frequency phase modulation of phosphorescent microprobes embedded in the tissue. Phase modulation is focus independent and unaffected by cell death or migration. This sensitive measurement of oxygen dynamics revealed important information on the drug mechanism of action and transient subthreshold effects. Specifically, exposure to antiarrhythmic agent, amiodarone, showed that both respiration and the time to onset of mitochondrial damage were dose dependent showing a TC50 of 425 μm. Analysis showed significant induction of both phospholipidosis and microvesicular steatosis during long-term exposure. Importantly, exposure to widely used analgesic, acetaminophen, caused an immediate, reversible, dose-dependent loss of oxygen uptake followed by a slow, irreversible, dose-independent death, with a TC50 of 12.3 mM. Transient loss of mitochondrial respiration was also detected below the threshold of acetaminophen toxicity. The phenomenon was repeated in HeLa cells that lack CYP2E1 and 3A4, and was blocked by preincubation with ascorbate and TMPD. These results mark the importance of tracing toxicity effects over time, suggesting a NAPQI-independent targeting of mitochondrial complex III might be responsible for acetaminophen toxicity in extrahepatic tissues.
KeywordsLiver on chip Acetaminophen Amiodarone Mitochondria Oxygen uptake Bioreactor
This work was funded by ERC Starting Grant TMIHCV (No. 242699), the British Council BIRAX Regenerative Medicine award (No. 33BX12HGYN), and the HeMibio consortium funded by the European Commission and Cosmetics Europe as part of the SEURAT-1 cluster (No. HEALTH-F5-2010-266777). Development of the OPAL system was funded by ILB project FeLas3D (No. 80149436).
- Löhmannsröben HG, Beck M, Hildebrandt N, Schmälzlin E, van Dongen JT (2006) New challenges in biophotonics: laser-based fluoroimmuno analysis and in vivo optical oxygen monitoring—art. no. 61570E. In: Gries W, Pearsall TP (eds) Workshop on Laser Applications in Europe. Proceedings of the Society of Photo-Optical Instrumentation Engineers (Spie), vol 6157. Spie-Int Soc Optical Engineering, Bellingham, p E1570–E1570Google Scholar
- Nahmias Y, Berthiaume F, Yarmush ML (2006) Integration of technologies for hepatic tissue engineering. In: Lee K, Kaplan D (eds) Advances in biochemical engineering/biotechnology, vol 103., SpringerBerlin, Heidelberg, pp 309–329Google Scholar
- Vinken M (2013) The adverse outcome pathway concept: a pragmatic tool in toxicology. Toxicology 312(1879–3185 (Electronic)):158–165Google Scholar